0.405

3.74% 0.0146

After Hours: .40 -0.005 -1.23%

China Sxt Pharmaceuticals Inc (SXTC)

Overview News Price History Discussions Forecast Stock Split

China Sxt Pharmaceuticals Inc stock is traded at $0.405, with a volume of 182.58K. It is up +3.74% in the last 24 hours and down -29.57% over the past month. China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

Previous Close:

$0.3904

Open:

$0.4088

24h Volume:

182.58K

Relative Volume:

0.33

Market Cap:

$1.63M

Revenue:

$1.93M

Net Income/Loss:

$-3.10M

P/E Ratio:

-0.0167

EPS:

-24.3081

Net Cash Flow:

$-1.93M

1W Performance:

+5.66%

1M Performance:

-29.57%

6M Performance:

-62.15%

1Y Performance:

-78.23%

1-Day Range:

$0.40

$0.4399

1-Week Range:

$0.3721

$0.4399

52-Week Range:

$0.3711

$6.39

China Sxt Pharmaceuticals Inc Stock (SXTC) Company Profile

Name

China Sxt Pharmaceuticals Inc

Sector

Healthcare (1200)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SXTC's Discussions on Twitter

Compare SXTC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SXTC China Sxt Pharmaceuticals Inc	0.405	1.63M	1.93M	-3.10M	-1.93M	-24.31
ZTS Zoetis Inc	176.74	80.59B	9.15B	2.43B	2.31B	4.92
HLN Haleon Plc Adr	9.72	44.17B	14.26B	1.55B	0	0.3327
TAK Takeda Pharmaceutical Co Adr	13.57	42.61B	30.27B	1.93B	3.45B	0.444
TEVA Teva Pharmaceutical Industries Ltd Adr	16.57	18.77B	16.77B	-959.00M	1.37B	-2.00
VTRS Viatris Inc	13.22	15.73B	15.05B	-883.30M	1.89B	1.53

China Sxt Pharmaceuticals Inc Stock (SXTC) Latest News

Nov 14, 2024

SXTC stock hits 52-week low at $0.43 amid sharp annual decline - Investing.com Australia

Nov 14, 2024

Nov 06, 2024

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.05% - MSN

Nov 06, 2024

Nov 02, 2024

SXTC stock touches 52-week low at $0.52 amid market challenges - Investing.com India

Nov 02, 2024

Nov 01, 2024

SXTC stock touches 52-week low at $0.52 amid market challenges By Investing.com - Investing.com South Africa

Nov 01, 2024

Oct 16, 2024

In the Green: China SXT Pharmaceuticals Inc (SXTC) Closes at 0.63, Up/Down 12.64 from Previous Day - The Dwinnex

Oct 16, 2024

SXTC’s Stock Market Adventure: -84.07% YTD Growth Amidst Volatility - The InvestChronicle

Oct 16, 2024

Oct 14, 2024

U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.05% - MSN

Oct 14, 2024

Oct 08, 2024

Visteon to Announce Third Quarter 2024 Results - The Manila Times

Oct 08, 2024

Oct 07, 2024

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency - The Manila Times

Oct 07, 2024

Oct 01, 2024

China SXT Pharmaceuticals Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle

Oct 01, 2024

Sep 30, 2024

SXTC’s price-to-free cash flow ratio: How it affects investment decisions - US Post News

Sep 30, 2024

Insider’s View: Deciphering China SXT Pharmaceuticals Inc (SXTC)’s Financial Health Through Ratios - The Dwinnex

Sep 30, 2024

Sep 26, 2024

SXTC’s Market Whiplash: -83.70% YTD Decline, -22.51% Plunge in 30 Days - The InvestChronicle

Sep 26, 2024

How does SXTC’s price to cash per share ratio compare in the market? - US Post News

Sep 26, 2024

Sep 25, 2024

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Significant Decline in Short Interest - Defense World

Sep 25, 2024

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Sees Large Increase in Short Interest - Defense World

Sep 25, 2024

Sep 20, 2024

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Quotes, Forecast and News Summary - Benzinga

Sep 20, 2024

Sep 19, 2024

China's First Generic Version of AstraZeneca's Xigduo XR Diabetes Pill Gets Green Light - Yicai Global

Sep 19, 2024

Sep 17, 2024

SIMPLY SOLVENTLESS PROVIDES Q3 2024 GUIDANCE INCLUDING RECORD PROJECTED QUARTERLY REVENUE AND EIGHTH STRAIGHT QUARTER OF NET INCOME PROFIT, AND ANNOUNCES UPCOMING PRODUCT LAUNCHES – Company A - Financial Times

Sep 17, 2024

Sep 16, 2024